J Korean Thyroid Assoc.  2015 May;8(1):14-18. 10.11106/cet.2015.8.1.14.

Low Dose versus High Dose Radioiodine Therapy

• Won KS

• KMID: 2149616
• DOI: http://doi.org/10.11106/cet.2015.8.1.14

Abstract

Since 1946, radioiodine (I-131) therapy has been one of the standard treatments for differentiated thyroid cancer (DTC). Recently the occurrence of thyroid cancer was markedly increasing and most of them were limited disease. Several reports said that there is no significant difference of outcome between low and high dose radioiodine therapy in patients with low to intermediate risk category of thyroid cancer. In this review, current effectiveness and toxicity of radioiodine ablation will be compared between low and high dose radioiodine in patient with low to intermediate risk DTC.

Keyword

Thyroid neoplasm; I-131; Therapy; Dose

MeSH Terms

Humans
Thyroid Neoplasms

Reference

References

1. Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ. et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012; 53(10):1633–51.

2. Park JM. Radioiodine therapy: review of the empiric fixed dose approaches and their selective applications. J Korean Thyroid Assoc. 2013; 6(1):34–42.

3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154(6):787–803.

4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules Differentiated Thyroid Cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167–214.

5. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009; 19(12):1381–91.

6. Paeng JC, Chung JK. Methods and clinical efficacy of dosimetry-based treatment in radioiodine therapy of thyroid cancer. J Korean Thyroid Assoc. 2013; 6(1):43–8.

7. Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol. 2000; 143(5):623–7.

8. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994; 97(5):418–28.

9. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004; 89(8):3668–76.

10. Yi KH, Park YJ, Koong SS, Kim JH, Na DG, Ryu JS. et al. Revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer. Endocrinol Metab. 2010; 25(4):270–97.

11. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR. et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010; 20(12):1423–4.

12. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffe S. et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012; 97(5):1526–35.

13. Nixon IJ, Ganly I, Patel S, Palmer FL, Whitcher MM, Tuttle RM. et al. The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery. 2011; 150(6):1242–9.

14. Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK. et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid. 2013; 23(6):683–94.

15. Creach KM, Siegel BA, Nussenbaum B, Grigsby PW. Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma. ISRN Endocrinol. 2012; 2012; 816386.

16. Mihailovic J, Stefanovic L, Stankovic R. Influence of initial treatment on the survival and recurrence in patients with differentiated thyroid microcarcinoma. Clin Nucl Med. 2013; 38(5):332–8.

17. Sawka AM, Goldstein DP, Brierley JD, Tsang RW, Rotstein L, Ezzat S. et al. The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study. PLoS One. 2009; 4(1):e4191.

18. Rosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid. 2013; 23(5):617–9.

19. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008; 93(2):504–15.

20. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE. et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003; 89(9):1638–44.

21. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD. et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009; 19(5):451–7.

22. Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 2012; 151(6):844–50.

23. Rosario PW, Tavares WC, Borges MA, Santos JB, Calsolari MR. Ultrasonographic differentiation of cervical lymph nodes in patients with papillary thyroid carcinoma after thyroidectomy and radioiodine ablation: a prospective study. Endocr Pract. 2014; 20(4):293–8.

24. Haugen BR. Radioiodine remnant ablation: current indications and dosing regimens. Endocr Pract. 2012; 18(4):604–10.

25. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab. 2004; 89(4):1666–73.

26. Bal C, Chandra P, Kumar A, Dwivedi S. A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer. Nucl Med Commun. 2012; 33(10):1039–47.

27. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L. et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012; 366(18):1674–85.

28. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B. et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012; 366(18):1663–73.

29. Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M. et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun. 2012; 33(3):275–82.

30. Kim EY, Kim TY, Kim WG, Yim JH, Han JM, Ryu JS. et al. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma. Nucl Med Commun. 2011; 32(10):954–9.

31. Cheng W, Ma C, Fu H, Li J, Chen S, Wu S. et al. Lowor high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J Clin Endocrinol Metab. 2013; 98(4):1353–60.

32. Valachis A, Nearchou A. High versus low radioiodine activity in patients with differentiated thyroid cancer: a meta-analysis. Acta Oncol. 2013; 52(6):1055–61.

33. Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia C. et al. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol. 2013; 169(1):23–9.